Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL EPS (Diluted)

EPS (Diluted) at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$0.69+81.6%
AVN
AVNSAVNS
$0.11-21.4%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$0.07-30.0%
Bioventus logo
BioventusBVS
$0.47+327%
Organon logo
OrganonOGN
$0.55+66.7%
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX
-$0.15+98.2%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income2,2892,3835,9954,608
(Loss) income before income taxes(13,532)17,0255,20820,147
Provision for income taxes1,5195,0425,7635,747
Net (loss) income$(15,051)$11,983$(555)$14,400
(Loss) earnings per share — basic$(0.46)$0.38$(0.02)$0.45
Weighted-average shares — basic32,460,78331,810,61232,275,15931,802,222
(Loss) earnings per share — diluted$(0.46)$0.34$(0.02)$0.44
Weighted-average shares — diluted32,460,78339,075,70332,275,15939,283,297

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s EPS (diluted)?
Collegium Pharmaceutical, Inc. (COLL) reported EPS (diluted) of -$0.46 in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s EPS (diluted) changed year-over-year?
Collegium Pharmaceutical, Inc.'s EPS (diluted) decreased by 235.3% year-over-year, from $0.34 to -$0.46.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s EPS (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from $1.69 to $1.71.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Collegium Pharmaceutical, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude